- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02836262
일차 고관절 전치환술의 고관절 교체 시스템(HRS-P) ((HRS-P))
일차 고관절 전치환술에서 고관절 혁신 기술(HIT) 고관절 교체 시스템에 대한 다기관 전향적 연구
To evaluate effectiveness and safety of HHRS in subjects undergoing total hip arthroplasty (THA). Effectiveness will be evaluated using patient-reported, clinical, radiologic, and radiostereometric outcomes. Safety will be evaluated through the collection of device-related and unanticipated device-related adverse events.
연구 개요
상세 설명
The HIT Hip Replacement System (HHRS) is a Metal-on-Polyethylene (MoP) conventional hip prosthesis. The HHRS consists of a femoral stem, an acetabular cup and a Cobalt Chromium Molybdenum (CoCrMo) ball that articulates within a polyethylene liner. The ball sits on the acetabular cup, and the polyethylene liner is attached to the femoral cup, which attaches to the femoral stem, instead of the acetabular cup. The acetabular component of the HHRS consists of a hemispherical acetabular shell with a clustered screw-hole design. The outside of the shells are coated with titanium plasma to facilitate bone in-growth and provide secure intermediate fixation with the prepared bone surface at the site of implantation. The acetabular cup has a 3-hole design that accommodates three titanium alloy bone screws. Inside the acetabular cup is a male taper for assembly with the acetabular ball. The femoral component consists of a femoral stem manufactured from titanium and a mating cobalt chrome femoral cup lined with a highly cross-linked ultra-high-molecular-weight polyethylene (UHMWPE). As with the acetabular cup, the femoral stem is porous coated using a plasma spray of pure titanium, which is intended to facilitate bone in-growth and provide secure intermediate fixation with the prepared bone surface at the site of implantation. The femoral stem incorporates a female taper for assembly with the male taper of the femoral cup.
The device has undergone extensive pre-clinical testing. There is no clinical experience with the HRS.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Linda Braddon, PhD
- 전화번호: 770-837-2681
- 이메일: LGB@SecureBME.com
연구 연락처 백업
- 이름: Thomas Turgeon, MD
- 전화번호: 204-926-1218
- 이메일: tturgeon@cjrg.ca
연구 장소
-
-
Manitoba
-
Winnipeg, Manitoba, 캐나다, R2K 2M9
- 모병
- Orthopaedic Innovation Centre
-
연락하다:
- Thomas Turgeon, MD
- 전화번호: (204) 926-1218
- 이메일: tturgeon@cjrg.ca
-
연락하다:
- Sarah Tran
- 전화번호: (204) 926-1231
- 이메일: stran@orthoinno.com
-
수석 연구원:
- Thomas Turgeon, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patient has a non-inflammatory degenerative joint disease (NIDJD) or any of its composite diagnoses such as osteoarthritis, avascular necrosis, traumatic arthritis, slipped capital epiphysis, fracture of the pelvis, and diastrophic variant requiring unilateral primary total hip replacement.
- Age between 65 and 79 years (inclusive) at the time of enrollment.
- Patient is a suitable candidate for primary total hip replacement at the discretion of the Investigator.
- Pre-surgery (within 28 days before surgery) WOMAC Global Score of 40 or larger on a scale from 0 (best) to 96 (worst)
- Signed and dated informed consent document.
- Patient is willing and able to participate in required follow-up visits at the Investigational site and to complete study procedures and questionnaires.
Exclusion Criteria:
- Patient has had total hip replacement, hemi-arthroplasty, or fusion in either hip in the last 12 months;
- Patient has planned total hip arthroplasty on a contra-lateral joint in the next 12 months;
- Patient has a known allergy to any component of the study device;
- Patient has a history of active sepsis in the joint;
- Patient has an insufficient acetabular or femoral bone stock in which good anchorage of the implants are unlikely or impossible;
- Patient has total or partial absence of the muscular or ligamentous apparatus;
- Patient has known moderate to severe renal insufficiency;
- Patient has vascular insufficiency, muscular atrophy, or neuromuscular disease in either leg (based on the Investigator's discretion);
- Patient has a deformity of the affected limb or significant anatomic variance of the affected hip;
- Patient has an active malignancy or history of invasive malignancy within the last five years, with the exception of superficial basal cell carcinoma or squamous cell carcinoma of the skin that has been definitively treated. Patients with carcinoma in situ of the uterine cervix definitively treated more than 1 year prior to enrollment may enter the study;
- Patient has any condition which may, in the opinion of the Investigator, interfere with the total hip replacement survival or patient outcomes (e.g. Paget's disease, Charcot's disease);
- Patient has rheumatoid arthritis or other autoimmune condition that affect joints (e.g. Lupus Arthritis);
- Patient has any condition that would interfere with patient self-assessment or pain, the function or quality of life required for patient reported outcomes during the study (based on the Investigator's discretion);
- Body Mass Index (BMI) of 40 or more;
- Patient has an active infection (e.g. hepatitis, AIDS, ARC) - systemic or at the site of intended surgery;
- Patient is currently participating in any investigational study not related to this study's pre-operative or post-operative care;
- Patient has any other severe acute or chronic medical condition that may interfere with the interpretation of the study results, in the judgment of the Investigator, which would make the patient inappropriate for entry into this study;
- Patient has a history of metabolic bone disease (e.g. Paget's disease or osteomalacia);
- Patient is currently pregnant or is planning to become pregnant.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: HIT Hip Replacement System (HRS)
Single group assignment with historical controls. |
HIT Hip Replacement System |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
웨스턴 온타리오 및 맥마스터 대학교 골관절염 지수(WOMAC) v3.0의 변화 리커트 척도 기능 제한 기준선(수술 전)과 수술 후 730일 추적 시점 사이의 점수.
기간: 수술 전 ~ 730일(24개월) 사이
|
수술 전 ~ 730일(24개월) 사이
|
|
기준선(수술 전)과 수술 후 730일 추적 시점 사이의 Harris Hip Score의 변화.
기간: 수술 전 ~ 730일(24개월) 사이
|
수술 전 ~ 730일(24개월) 사이
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
수술 후 730일과 기준선(수술 전) 사이의 Oxford Hip Score의 변화
기간: 수술 후 730일과 기준선(수술 전) 사이
|
수술 후 730일과 기준선(수술 전) 사이
|
|
수술 후 730일과 기준선(수술 전) 사이의 Short Form 36 v2 신체 구성 요소 점수(PCS)의 변화
기간: 수술 후 730일과 기준선(수술 전) 사이
|
수술 후 730일과 기준선(수술 전) 사이
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Thomas Turgeon, MD, Orthopaedic Innovation Centre
- 연구 책임자: Branko Kopjar, MD, PhD, Nor Consult, LLC
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .